+357 96 030922
info@marketpublishers.com

Global Long-acting Anti-HIV Drugs Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/G52DE0ACA4D1EN.html
Date: February 2026
Pages: 91
Price: US$ 4,480.00 (Single User License)
ID: G52DE0ACA4D1EN

Abstracts

The global Long-acting Anti-HIV Drugs market size is expected to reach $ 817 million by 2032, rising at a market growth of 14.8% CAGR during the forecast period (2026-2032).

Long-acting anti-HIV drugs are antiretroviral products formulated with extended-release technologies to maintain therapeutic drug exposure over prolonged intervals, enabling HIV treatment (ART) or prevention (PrEP) to be delivered weekly, monthly, or even less frequently rather than requiring daily oral dosing. They are designed to address real-world adherence and stigma-related barriers: durable viral suppression depends on consistent medication intake, yet missed doses, treatment fatigue, irregular routines, and privacy concerns can undermine outcomes and increase transmission risk; long-acting dosing reduces pill burden and the day-to-day “reminder” of therapy, improving continuity of care and quality of life while expanding prevention options for people who struggle with daily PrEP. Historically, HIV care progressed from early multi-pill oral regimens toward potent combination therapies with better safety and resistance profiles, after which innovation increasingly focused on delivery and adherence; advances in formulation science and drug-delivery platforms enabled extended-release approaches such as intramuscular or subcutaneous injections and implants, using technologies like nanosuspensions, microspheres, lipid/polymer carriers, or controlled-release matrices to provide predictable exposure over time. The upstream supply chain typically spans active pharmaceutical ingredients and key intermediates (specialty chemicals, chiral reagents, solvents, catalysts), formulation excipients (biodegradable polymers such as PLGA, lipids, surfactants, stabilizers, and release-controlling matrices), and sterile delivery/packaging inputs (prefilled syringes and needle components, rubber stoppers and seals, sterile filters, glass or high-barrier polymer containers), along with critical manufacturing and quality-control “components” (single-use fluid paths, pumps/valves, isolator and HEPA filtration elements, in-line sensors for particle size/viscosity, cold-

+357 96 030922
info@marketpublishers.com

chain temperature indicators). Because long-acting products place tighter constraints on sterility assurance, particle-size distribution, release-profile consistency, and storage stability, upstream material quality systems and regulatory-grade traceability are often decisive for batch release and reliable commercial supply.In 2025, global production capacity for long-acting anti-HIV drugs reached 150,000 doses, while sales totaled 130,200 doses. The average selling price was approximately USD 2,312 per dose, and gross margins across manufacturers were in the range of 60%–70%.

In the current market landscape, long-acting anti-HIV therapy and prevention are moving from “clinically feasible” to “real-world deployable,” with commercialization increasingly shaped by adherence outcomes, service accessibility, and reimbursement pathways rather than efficacy alone. In practice, adoption tends to concentrate in populations where daily dosing is challenging due to unstable routines, pill fatigue, or privacy concerns, while broader rollout depends heavily on care delivery readiness—standardized visit scheduling, repeatable injection workflows, cold-chain and inventory control, and robust management of adverse events and the so-called pharmacokinetic “tail.” As clinicians and patients gain experience, conversations are shifting from whether long-acting options work to who benefits most, how to switch safely, and how to sustain therapy over time, with stronger integration into sexual health clinics, community programs, and public health initiatives—making “drug plus service” the de facto product.

Looking ahead, innovation is likely to track toward longer dosing intervals, more stable exposure, higher resistance barriers, simpler administration, and a better patient experience, supported by multiple delivery platforms in parallel. On the regimen side, development momentum favors combinations and strategies that maintain a strong barrier to resistance and reduce vulnerability during transitions or missed visits. On the formulation side, continued optimization of nanosuspensions, microspheres, lipid/polymer carriers, and implants aims to improve injection volume, local tolerability, release predictability, and storage/transport stability. On the system side, care models will diversify beyond conventional clinic injections, pairing long-acting dosing with telehealth follow-up, community-based administration, mobile care teams, and digital tools for appointment and adherence management, creating delivery pathways that better match local resource constraints. In prevention settings, long-acting options may enable more sustainable coverage for higher-risk groups by reducing discontinuation and improving continuity of protection.

The market is propelled and constrained by forces that operate simultaneously. Key drivers include public health priorities around sustained suppression and sustained

+357 96 030922
info@marketpublishers.com

prevention, patient demand for improved quality of life and discretion, and payer interest in avoiding lapses that lead to complications and onward transmission; on the industry side, maturation of formulation platforms, sterile manufacturing capabilities, and increasingly standardized service delivery all support uptake. Major barriers include access limitations inherent to facility-based administration, operational burdens from cold-chain and inventory requirements, management of injection-site reactions and long-term tolerability, and the resistance and transmission risks associated with interruption during the drug “tail,” which necessitate disciplined screening, follow-up, and contingency plans. Regional variation in regulation, procurement, and reimbursement can further slow penetration, while stigma, information gaps, and suboptimal service experiences may undermine persistence. As a result, competitive advantage will increasingly hinge not only on the molecule, but on end-to-end capabilities across screening, dosing, follow-up, supply assurance, and risk management.

This report studies the global Long-acting Anti-HIV Drugs production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Long-acting Anti-HIV Drugs and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Long-acting Anti-HIV Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Long-acting Anti-HIV Drugs total production and demand, 2021-2032, (K Dose)
Global Long-acting Anti-HIV Drugs total production value, 2021-2032, (USD Million)
Global Long-acting Anti-HIV Drugs production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Long-acting Anti-HIV Drugs consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Long-acting Anti-HIV Drugs domestic production, consumption, key domestic manufacturers and share
Global Long-acting Anti-HIV Drugs production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Long-acting Anti-HIV Drugs production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Long-acting Anti-HIV Drugs production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)

+357 96 030922
info@marketpublishers.com

This report profiles key players in the global Long-acting Anti-HIV Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ViiV Healthcare, Janssen Pharmaceuticals, Gilead Sciences, Theratechnologies, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Long-acting Anti-HIV Drugs market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Long-acting Anti-HIV Drugs Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

+357 96 030922
info@marketpublishers.com

Global Long-acting Anti-HIV Drugs Market, Segmentation by Type:

Single Drug

Combination Preparation

Global Long-acting Anti-HIV Drugs Market, Segmentation by Dosing Interval:

Short-interval Injections

Monthly Injections

Quarterly Injections

Global Long-acting Anti-HIV Drugs Market, Segmentation by Drug Properties:

Original Drug

Generic Drug

Global Long-acting Anti-HIV Drugs Market, Segmentation by Application:

Hospital

Clinic

Other

Companies Profiled:

ViiV Healthcare

Janssen Pharmaceuticals

Gilead Sciences

+357 96 030922
info@marketpublishers.com

Theratechnologies

Key Questions Answered:

1. How big is the global Long-acting Anti-HIV Drugs market?
2. What is the demand of the global Long-acting Anti-HIV Drugs market?
3. What is the year over year growth of the global Long-acting Anti-HIV Drugs market?
4. What is the production and production value of the global Long-acting Anti-HIV Drugs market?
5. Who are the key producers in the global Long-acting Anti-HIV Drugs market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

5 MARKET ANALYSIS BY TYPE

6 MARKET ANALYSIS BY ASSET TYPE

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

9 COMPANY PROFILES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Long-acting Anti-HIV Drugs Supply, Demand and Key Producers, 2026-2032
Product link: https://marketpublishers.com/r/G52DE0ACA4D1EN.html
Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G52DE0ACA4D1EN.html